Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

New MMP inhibitor disclosed by Agouron

April 18, 1997

New COX-2 inhibitor from Searle

April 15, 1997

Immunex's Enbrel demonstrates positive safety profile in RA patients

April 14, 1997

Wyeth-Ayerst and Elan develop new formulation of Lodine

April 11, 1997

NitroMed/J&J divisions collaborate on NSAID/NO donor compounds

April 9, 1997

Pivotal trial of Therafectin enrolled

April 3, 1997

Wyeth-Ayerst describes antiinflammatory agents

April 2, 1997

Protein Design Labs grants license to IDEC for humanized MAb

March 25, 1997

Antiinflammatory protein described by New York University

March 25, 1997

Fujisawa describes compound for autoimmune diseases

March 24, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...